Apigenin induces apoptosis by regulating Akt and MAPK pathways in human melanoma cell A375SM.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 13 03 2020
accepted: 08 09 2020
pubmed: 12 11 2020
medline: 14 5 2021
entrez: 11 11 2020
Statut: ppublish

Résumé

Apigenin, an aromatic compound, exhibits antioxidant, anti‑inflammatory and anti‑viral effects. The present study aimed to investigate the effects of apigenin on cell proliferation and apoptosis of human melanoma cells A375P and A375SM. Therefore, melanoma cells were treated with apigenin to determine its anti‑proliferative and survival effects, using wound healing and MTT assays. The results revealed that melanoma cell viability was decreased in a dose‑dependent manner. Furthermore, chromatin condensation, indicating apoptosis, was significantly increased in a dose‑dependent manner, as demonstrated by DAPI staining. In addition, increased apoptosis rate following treatment with apigenin was confirmed by Annexin V‑propidium iodide staining. The changes in the expression levels of apoptosis‑related proteins in A375P and A375SM melanoma cells were subsequently detected using western blot analysis. The results demonstrated that the protein expression levels of Bcl‑2 were decreased, whereas those of Bax, cleaved poly ADP‑ribose polymerase, cleaved caspase‑9 and p53 were upregulated in a dose‑dependent manner in apigenin‑treated cells compared with those noted in untreated cells. In addition, in apigenin‑treated A375P cells, phosphorylated (p)‑p38 was upregulated and p‑extracellular signal‑regulated kinase (ERK), p‑c‑Jun N‑terminal kinase (JNK) and p‑protein kinase B (Akt) were downregulated. However, in A375SM cells, apigenin treatment increased p‑ERK and p‑JNK and decreased p‑p38 and p‑Akt protein expression levels. Subsequently, the inhibitory effect of apigenin on tumor growth was investigated in vivo. Tumor volume was significantly reduced in the 25 and 50 mg/kg apigenin‑treated groups compared with the control group. Additionally, a TUNEL assay was performed to detect apoptotic cells. Immunohistochemical staining also revealed elevated p‑ERK expression in the apigenin‑treated group compared with the control group. Overall, the findings of the present study indicated that apigenin attenuated the growth of A375SM melanoma cells by inducing apoptosis via regulating the Akt and mitogen‑activated protein kinase signaling pathways.

Identifiants

pubmed: 33174048
doi: 10.3892/mmr.2020.11572
pmc: PMC7646940
doi:

Substances chimiques

Apoptosis Regulatory Proteins 0
Proto-Oncogene Proteins c-bcl-2 0
Apigenin 7V515PI7F6
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Extracellular Signal-Regulated MAP Kinases EC 2.7.11.24
JNK Mitogen-Activated Protein Kinases EC 2.7.11.24
CASP9 protein, human EC 3.4.22.-
Caspase 9 EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4877-4889

Références

Int J Oncol. 2007 Jan;30(1):233-45
pubmed: 17143534
Eur J Cancer. 1999 Oct;35(10):1517-25
pubmed: 10673981
J Cell Physiol. 2006 Apr;207(1):23-9
pubmed: 16222712
Apoptosis. 2004 Nov;9(6):667-76
pubmed: 15505410
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Arzneimittelforschung. 1993 Mar;43(3):370-2
pubmed: 7683883
Mol Carcinog. 2004 Feb;39(2):114-26
pubmed: 14750216
EMBO J. 1999 Jan 4;18(1):167-78
pubmed: 9878060
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
Oncol Lett. 2017 Mar;13(3):1041-1047
pubmed: 28454211
Zhonghua Zhong Liu Za Zhi. 2007 Jul;29(7):495-9
pubmed: 18069627
Nutrients. 2019 Apr 16;11(4):
pubmed: 30995771
Science. 1998 Aug 28;281(5381):1322-6
pubmed: 9735050
Trends Plant Sci. 1999 Oct;4(10):394-400
pubmed: 10498963
Int J Mol Sci. 2017 Mar 17;18(3):
pubmed: 28304343
Cell Cycle. 2007 May 2;6(9):1102-14
pubmed: 17457054
Front Biosci. 1998 Sep 15;3:D1005-10
pubmed: 9740553
Environ Toxicol. 2017 Feb;32(2):434-444
pubmed: 26872304
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Carcinogenesis. 2008 Nov;29(11):2210-7
pubmed: 18725386
BMB Rep. 2008 Jan 31;41(1):1-10
pubmed: 18304444
Mol Cancer. 2011 Aug 29;10:104
pubmed: 21871133
Toxicol Appl Pharmacol. 2008 Jan 15;226(2):178-91
pubmed: 17961621
Cancer Res. 1992 Apr 1;52(7 Suppl):2024s-2029s
pubmed: 1311987
Eur J Pharmacol. 2007 Dec 8;576(1-3):26-33
pubmed: 17716651
Oncol Rep. 2017 Apr;37(4):2277-2285
pubmed: 28260058
Cancer Lett. 2008 Jan 18;259(1):39-49
pubmed: 17967505
J Ethnopharmacol. 2008 Oct 30;120(1):1-6
pubmed: 18721870
J Biomed Sci. 2009 May 27;16:49
pubmed: 19473507
Melanoma Res. 2008 Oct;18(5):322-9
pubmed: 18781130
J Leukoc Biol. 2001 Jan;69(1):3-10
pubmed: 11200064
Int J Cancer. 2000 Aug 15;87(4):595-600
pubmed: 10918203
Food Funct. 2019 Feb 20;10(2):514-528
pubmed: 30746536
Neoplasma. 2001;48(2):104-7
pubmed: 11478688
Cell Growth Differ. 1998 Aug;9(8):687-97
pubmed: 9716185
PLoS One. 2014 Oct 16;9(10):e110429
pubmed: 25330384
J Nutr Biochem. 2009 Apr;20(4):285-90
pubmed: 18656338
Cell Biol Int. 1993 May;17(5):461-76
pubmed: 8339064
Cell Growth Differ. 2001 Aug;12(8):397-408
pubmed: 11504705
Curr Pharm Des. 2010 Jan;16(1):34-44
pubmed: 20214616
Biomed Res Int. 2019 Oct 16;2019:7010467
pubmed: 31737673
Oncogene. 1999 Nov 1;18(45):6087-93
pubmed: 10557099
Development. 2018 Jul 26;145(14):
pubmed: 30049820
Arch Biochem Biophys. 2018 May 15;646:107-112
pubmed: 29580946
Cell. 2004 Jan 23;116(2):205-19
pubmed: 14744432
Cancer Res. 2006 Apr 15;66(8):3963-6
pubmed: 16618711
Int J Mol Sci. 2018 Nov 09;19(11):
pubmed: 30423952
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
pubmed: 16514137
Life Sci. 2016 Oct 1;162:77-86
pubmed: 27569589
Phytomedicine. 2019 May;58:152893
pubmed: 30901663
Nutrients. 2018 Aug 04;10(8):
pubmed: 30081573
Planta Med. 2010 Aug;76(11):1075-9
pubmed: 20486070
Lancet. 2002 Jun 1;359(9321):1921-2
pubmed: 12057558
Am J Cancer Res. 2014 Nov 19;4(6):674-82
pubmed: 25520859
Cancer Res Treat. 2014 Apr;46(2):109-23
pubmed: 24851102

Auteurs

Joong-Seok Woo (JS)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Gang-Sik Choo (GS)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Eun-Seon Yoo (ES)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Sung-Hyun Kim (SH)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Jae-Han Lee (JH)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

So-Hee Han (SH)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Hyeong-Jin Kim (HJ)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Soo-Hyun Jung (SH)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Young-Seok Park (YS)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Byeong-Soo Kim (BS)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Sang-Ki Kim (SK)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Byung-Kwon Park (BK)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Sung-Dae Cho (SD)

Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080, Republic of Korea.

Jeong-Seok Nam (JS)

Gwangju Institute of Science and Technology, School of Life Sciences, Gwangju 61005, Republic of Korea.

Chang-Sun Choi (CS)

Biomedical Center for Animal Resource Development, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

Jeong-Hwan Che (JH)

Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.

Ji-Youn Jung (JY)

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungcheongnam 32439, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH